

GROENHUYSEN WILHELMUS CM

Form 4

July 30, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**GROENHUYSEN WILHELMUS CM**

(Last) (First) (Middle)

C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300

(Street)

MALVERN, PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
NovoCure Ltd [NVCR]

3. Date of Earliest Transaction (Month/Day/Year)  
07/27/2018

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Ordinary Shares	07/27/2018		S	3,710	D	\$ 33.86 (1)	175,602 D
Ordinary Shares	07/27/2018		S	17,437	D	\$ 34.44 (2)	158,165 D
Ordinary Shares	07/27/2018		S	34,385	D	\$ 35.2 (3)	123,780 D
Ordinary Shares	07/27/2018		S	6,095	D	\$ 36.6 (4)	117,685 D

Ordinary Shares 07/27/2018 S 1,100 D 37.05 116,585 D  
 \$ (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Benef Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director 10% Owner Officer Other

GROENHUYSEN WILHELMUS CM  
 C/O NOVOCURE INC.,  
 20 VALLEY STREAM PARKWAY, SUITE 300  
 MALVERN, PA 19355

Chief Financial Officer

## Signatures

Kimberly Burke, attorney in fact for Wilhelmus CM Groenhuisen

07/30/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 3,710 shares in multiple trades at prices ranging from \$33.70 to \$33.95. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the

## Edgar Filing: GROENHUYSEN WILHELMUS CM - Form 4

number of shares and prices at which the transaction was effected.

(2) On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 17,437 shares in multiple trades at prices ranging from \$34.00 to \$34.98. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

(3) On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 34,385 shares in multiple trades at prices ranging from \$35.00 to \$35.90. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

(4) On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 6,095 shares in multiple trades at prices ranging from \$36.00 to \$36.95. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

(5) On July 27, 2018, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuisen, Mr. Groenhuisen sold 1,100 shares in multiple trades at prices ranging from \$37.00 to \$37.10. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.